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Previous meta-analyses of psychotherapies for child and adolescent depression were limited because of the small number of trials with direct 
comparisons between two treatments. A network meta-analysis, a novel approach that integrates direct and indirect evidence from randomized 
controlled studies, was undertaken to investigate the comparative efficacy and acceptability of psychotherapies for depression in children and 
adolescents. Systematic searches resulted in 52 studies (total N53805) of nine psychotherapies and four control conditions. We assessed the 
efficacy at post-treatment and at follow-up, as well as the acceptability (all-cause discontinuation) of psychotherapies and con-trol conditions. 
At post-treatment, only interpersonal therapy (IPT) and cognitive-behavioral therapy (CBT) were significantly more effective than most control 
conditions (standardized mean differences, SMDs ranged from -0.47 to -0.96). Also, IPT and CBT were more beneficial than play therapy. Only 
psychodynamic therapy and play therapy were not significantly superior to waitlist. At follow-up, IPT and CBT were significantly more effective 
than most control conditions (SMDs ranged from -0.26 to -1.05), although only IPT retained this superiority at both short-term and long-term 
follow-up. In addition, IPT and CBT were more beneficial than problem-solving therapy. Waitlist was significantly inferior to other control 
conditions. With regard to acceptability, IPT and problem-solving therapy had significantly fewer all-cause discontinuations than cognitive 
therapy and CBT (ORs ranged from 0.06 to 0.33). These data suggest that IPT and CBT should be considered as the best available 
psychotherapies for depression in children and adolescents. However, several alternative psychotherapies are understudied in this age group. 
Waitlist may inflate the effect of psychotherapies, so that psychological placebo or treatment-as-usual may be preferable as a control condition 
in psychotherapy trials.
Depression in young people has significant developmen-
tal implications, and accounts for the greatest burden of dis-
ease in this age group (1). The point prevalence of depres-
sion ranges from 1.9 to 3.4% among primary school children 
and from 3.2 to 8.9% among adolescents, and the incidence 
peaks around puberty (2-4). The average duration of a 
depressive episode in children and adolescents is about nine 
months, and 70% of patients whose depression remits will 
subsequently develop another depressive episode within 
five years, which suggests a substantial continuity between 
child and adolescent depression and depression in adult-
hood (3,4). Moreover, due to the atypical presentation and 
the high frequency of comorbidities (5,6), many cases of 
child and adolescent depression remain undetected, and do 
not receive the treatments they need (7-9). Thus, youths 
with depression experience serious impairment in social 
functioning, e.g. poor school achievement and relational 
problems with family members and peers (10), and show an 
elevated risk of self-harm and suicidal behaviors (11).
Clinical practice guidelines recommend that psychotherapy 
be considered as the first-line treatment for the management 
of mild to moderate depression in children and adolescents 
(12-15), and that medications be reserved for severe cases and 
those in which psychotherapy does not work (12,13). From 
the U.S., it is known that approximately three-quarters of the 
adolescents treated for depression have received some form of 
psychotherapy (16). Controversy regarding the efficacy and 
safety of antidepressant medications, along with the evidence 
of an increased risk of suicidal behavior in children and 
adolescents treated with some of these medications, has 
focused attention on the use of psychotherapy for this young 
population (17-21).
A number of psychotherapies are currently available for  
treating depression in children and adolescents (22,23). 
Although there is a broad consensus that various 
psychotherapies are beneficial for depression in youth 
patients, recent systematic reviews and meta-analyses have 
questioned this notion (24-28). The effect sizes of cognitive-
behavioral
therapy (CBT) have recently decreased (24) compared to
those documented in earlier meta-analyses (25). Some
meta-analyses have reported that CBT is superior to other
psychotherapies (26,27), whereas others have suggested
that non-cognitive treatments (e.g., interpersonal therapy,
IPT) work as well as cognitive ones (24,28). However, the
conclusions of previous traditional meta-analyses were
based on a limited number of trials with direct compari-
sons between two treatments, while some treatments have
rarely or never been directly compared in a randomized
controlled trial (RCT).
We implemented a network meta-analysis, a new 
methodological approach that allows the simultaneous 
comparison of multiple psychotherapeutic interventions 
within a single analysis, while preserving randomization 
(29). This approach was applied to integrate direct 
evidence (from studies directly comparing interventions) 
with indirect evidence (information about two treatments 
derived via a common comparator, e.g. waitlist) to estimate 
the comparative efficacy and acceptability of all treatments 
(30).
We previously investigated in this way the comparative 
efficacy of psychotherapies for adult depressed patients (31) 
and of augmentation agents in adult treatment-resistant 
depression (32). The aim of the current network meta-
analysis was to provide a comprehensive and hierarchical 
evidence of the efficacy and acceptability of all 
psychotherapies in the treatment of depression in children 
and adolescents.
METHODS
Study protocol and search strategy
This systematic review is reported using PRISMA guide-
lines. The protocol has been registered with PROSPERO
(CRD42014010014) and published in BMJ Open (33).
Eight electronic databases – PubMed, EMBASE, 
Cochrane, Web of Science, PsycINFO, CINAHL, LILACS, 
and ProQuest Dissertations – were searched from January 1, 
1966 to July 1, 2014 with medical subject headings (MeSH) 
and text words. Also, ClinicalTrials.gov, the World Health 
Organization’s trial portal and U.S. Food and Drug 
Administration (FDA) reports were reviewed. No language 
restrictions or restrictions on publication type were applied.
Additional studies were searched for in the reference lists
of all identified publications, including relevant meta-
analyses and systematic reviews. Relevant authors were
contacted to supplement incomplete reports in the original
papers or to provide new data of unpublished studies.
Study selection
Two independent researchers (BQ and YYL) 
selected studies for inclusion, with divergences resolved 
by consensus. They scanned citations at the title/
abstract level and
then retrieved a shortlist of potentially relevant studies in
full text. These articles were reviewed in full to ensure that
they satisfied all of the following criteria.
Only prospective RCTs, including cross-over and cluster-
randomized trials, were selected. The study population had
to consist of children or adolescents (aged from 6 to 18 years
when initially enrolled in the primary study) who either had a
diagnosis of major depression, minor depression, intermittent
depression, or dysthymia based on standardized diagnostic
interviews, or exceeded a predefined threshold for depressive
symptoms using a validated depression severity measure.
Interventions included any manualized or structured 
psychotherapy, such as behavioral therapy, cognitive 
therapy, CBT, family therapy, IPT, play therapy, 
problem-solving therapy, psychodynamic therapy, and 
supportive therapy, regardless of duration and number of 
treatment sessions. RCTs comparing different modalities of 
the same type of psychotherapy (face-to-face, Internet or 
telephone), different treatment conditions (CBT or CBT plus 
sessions for parents) or different intervention formats (group 
or individual) were considered as the same node in the 
network analysis.
Comparators included another class of psychotherapy 
or a control condition, such as waitlist, no-treatment, 
treatment-as-usual, or psychological placebo.
To reduce inconsistency among trials, we excluded 
studies which recruited patients with treatment-resistant or 
psychotic depression; or involved combination therapies 
(i.e., combination of different psychological interventions, 
combination of psychotherapy with pharmacotherapy or 
another non-psychotherapeutic intervention); or focused 
on maintenance treatment or relapse prevention; or in 
which the psychotherapy intervention was not specifically 
aimed to treat depression. Studies were deemed eligible if 
they included patients with comorbid psychiatric disorders.
Outcome measures
The primary outcome was efficacy at post-treatment, as
measured by mean change scores in depressive symptoms
(self- or assessor-rated) from baseline to post-treatment.
The secondary outcome was efficacy at follow-up, as mea-
sured by mean change scores in depressive symptoms
from baseline to the end of follow-up. In addition, we
extracted the data for short-term (1 to 6 months) and
long-term (6 to 12 months) follow-up in each study. If a
study reported data for more than one time within our
pre-defined follow-up periods, we considered the last
time point within the range. If participants received fur-
ther treatments after the initial trial (e.g., continuous
treatment or booster sessions), they were not included in
the follow-up analysis.
Where depression symptoms were measured in a trial
using more than one scale, we extracted data for the scale
with the highest rank in a pre-defined hierarchy, based on
psychometric properties and appropriateness for use with
children and adolescents and on consistency of use across 
trials (18). The Children’s Depression Rating Scale 
(CDRSR (34) was adapted for children and adolescents 
from the Hamilton Depression Rating Scale (HAMD (35), 
a tool vali-dated and commonly used in adult 
populations. Both the CDRS-R and the HAMD have 
good reliability and validity (36) and had the highest 
rank in the hierarchy. The Beck Depression Inventory 
(BDI (37) and the Children’s Depres-sion Inventory (CDI 
(38) were the most commonly used among depression 
symptom severity self-rated scales and were ranked the 
second highest in the hierarchy.
The acceptability of treatment was operationally defined
as all-cause discontinuation, as measured by the proportion
of patients who discontinued treatment up to the post-
intervention time point.
Data extraction and risk of bias assessment
Two independent researchers (BQ and YYL) classified
psychotherapy approaches, extracted the data and assessed
the risk of bias with good inter-rater agreement (kappa50.86
to 0.90). The researchers independently extracted the key
study parameters using a standardized data abstraction form
and assessed the risk of bias in trials using the risk of bias tool
from the Cochrane Handbook (39). Any disagreements were
discussed with a third researcher (XYZ).
Data synthesis and analysis
We performed Bayesian network meta-analysis to compare 
the relative efficacy and acceptability of different 
psychotherapies and control conditions with each other from 
the median of the posterior distribution (29,30). The pooled 
estimates of standardized mean difference (SMD) with 95%
credible intervals (CrIs) were calculated for continuous 
outcomes, and odds ratios (ORs) with 95% CrIs for 
categorical outcomes. The SMD is the difference in mean 
change scores from baseline to post-treatment between two 
groups divided by the pooled standard deviation (SD) of the 
measurements, with a negative SMD value indicating greater 
symptomatic relief (39). In the presence of minimally 
informative priors, CrIs can be interpreted similarly to 
confidence intervals, and at conventional levels of statistical 
significance a two-sided p<0.05 can be assumed if 95% CrIs 
do not include 0 (30).
A Cohen’s effect size with Hedges’ correction for small
sample bias was calculated for all comparisons contained in
the studies (40). If means and SDs were not provided, we
calculated them from the p value or other statistical indices
as described elsewhere (41). Results from intention-to-treat
analysis (ITT) or modified ITT were preferred over results
from completer analyses.
The pooled estimates were obtained using the Markov
Chains Monte Carlo method. Two Markov chains were run
simultaneously with different arbitrarily chosen initial val-
ues. To ensure convergence, trace plots and the Brooks-
Gelman-Rubin statistic were assessed (42). Convergence 
was found to be adequate after running 50,000 samples for 
both chains. These samples were then discarded as 
“burn-in”, and posterior summaries were based on 100,000 
subsequent simulations. The node splitting method was 
used to calculate the inconsistency of the model, which 
separated evidence on a particular comparison into direct 
and indirect evidence (43). Probability values were 
summarized and reported as surface under the 
cumulative ranking curve (SUCRA) and rankograms, a 
simple transformation of the mean rank used to provide 
a hierarchy of the treatments and accounting for both the 
location and the variance of all relative treatment effects 
(44).
Network meta-analysis was performed using the Win-
BUGS software package (version 1.4.3, MRC Biostatistics
Unit, Cambridge, UK) with random effects models for
multi-arm trials. The other analyses were performed and
presented by the Stata 11.0 and R 2.11.1 software packages.
We conducted subgroup analyses of data on primary out-
come (efficacy in post-treatment) using the meta-regression
model and calculating Somer’s D (a correlation coefficient
for a dichotomous and an ordinal variable) (45). We consid-
ered sex ratio (male-to-female ratio >1 vs. <1); age group
(children aged 6-12 years vs. adolescents aged 13-18 years);
number of sessions planned (!8 vs. >8 sessions); interven-
tion format (group vs. individual); method for defining the
presence of depression (diagnosis of major depression, minor
depression or dysthymia vs. severity of depressive symp-
toms); comorbid psychiatric disorders (with vs. without); risk
of bias (“high risk” vs. “unclear risk” or “low risk”); sample
size (!50 vs. >50 patients); and year of publication (prior to
2000 vs. 2000 or following).
RESULTS
We analyzed 52 RCTs (46-97), including 116 conditions
(psychotherapies and control conditions) and 3,805 patients
(see the flow chart in Figure 1). Overall, 2,361 patients were
randomized to nine psychotherapies (CBT, N51149; IPT,
N5344; supportive therapy, N5244; cognitive therapy,
N5230; family therapy, N5134; play therapy, N5105;
behavioral therapy, N576; problem-solving therapy, N544;
or psychodynamic therapy, N535). The remaining 1,444
patients were randomized to four control conditions (wait-
list, N5419; no-treatment, N5284; treatment-as-usual,
N5432; or psychological placebo, N5309).
The RCTs were published between 1980 and 2013. Sam-
ple sizes ranged from 9 to 399 patients per trial, with a medi-
an of 73. About three-fifths of total participants (59.9%)
were females. Ten trials involved children only, 37 adoles-
cents only, and five both. The mean age of participants was
14.7 years (range: 7-18 years). The mean number of sessions
planned for psychotherapy was 11.4 (range: 5-36 sessions).
Further descriptive information about the included studies
is given in Table 1.
Twenty-one studies (40%) investigated depressive 
disorders with standardized diagnostic assessments, 
while 27 (52%) explored depressive symptoms with a 
validated depression severity measure, and the remaining 
four used both methodologies. The median duration of 
acute phase
treatment was 9.5 weeks (range: 4-36 weeks); that of follow-
up period was 8.1 months (range: 1-24 months).
The risk of bias was rated as low concerning randomized
generation of the allocation sequence in 25 RCTs, allocation
concealment in six RCTs, masking of outcome assessors to
treatment allocation in 20 RCTs, incomplete outcome data
in 28 RCTs, and selective reporting in 46 RCTs.
Figure 1 Flow chart of study selection
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There were 13 nodes (nine psychotherapies plus four 
control conditions) and 33 comparisons in the network plot 
of evidence (Figure 2). Results of efficacy at post-treatment 
and follow-up assessments are shown in Figure 3. Concern-
ing efficacy at post-treatment, only two psychotherapies 
(IPT and CBT) were significantly more effective than most 
control conditions, including psychological placebo, 
treatment-as-usual and waitlist (SMDs ranged from 20.47 
to 20.96). IPT and CBT were also significantly more 
benefi-cial than play therapy (SMDs520.93 and 20.80, 
respectively). Among the nine investigated 
psychotherapies, only psychodynamic therapy and play 
therapy were not signifi-cantly more beneficial than 
waitlist. Waitlist was significant-ly inferior to no-treatment 
(SMD520.46).
Concerning efficacy at follow-up, IPT and CBT were sig-
nificantly more effective than most control conditions,
including treatment-as-usual, waitlist and, for CBT, no-
treatment (SMDs ranged from 20.26 to 21.05). Also, IPT
and CBT were significantly more beneficial than problem-
solving therapy (SMDs521.10 and 20.90, respectively).
Psychodynamic therapy and problem-solving therapy were
not significantly more beneficial than waitlist. Waitlist was
significantly inferior to all other control conditions, includ-
ing placebo, treatment-as-usual, and no-treatment (SMDs
ranged from 20.53 to 20.67).
Data about acceptability are shown in Figure 4. IPT and 
problem-solving therapy had significantly fewer all-cause 
discontinuations than CBT and cognitive therapy (ORs 
ranged from 0.06 to 0.33). Problem-solving therapy also 
had significantly fewer discontinuations than psychological 
placebo (OR50.10; 95% CrI: 0.02 to 0.98).
Concerning efficacy at short-term follow-up, IPT was 
significantly more effective than problem-solving therapy 
and waitlist (SMDs520.99 and 20.95, respectively), and 
CBT was significantly more effective than cognitive 
therapy, problem-solving therapy, psychological placebo, 
and wait-list (SMDs ranged from 20.35 to 20.91). 
Behavioral therapy and supportive therapy were superior 
to waitlist (SMDs520.71, and 20.67, respectively). 
Waitlist was significantly inferior to psychological placebo 
(SMD520.52). In the analysis of efficacy at long-term 
follow-up, IPT was significantly more beneficial than CBT, 
cognitive therapy,
Figure 2 Network plot of evidence of all trials. The width of the lines is proportional to the number of trials comparing every pair of treatments,
and the size of every node is proportional to the number of randomized participants. BT – behavioral therapy, CBT – cognitive-behavioral therapy,
CT – cognitive therapy, FT – family therapy, IPT – interpersonal therapy, NT – no-treatment control, PBO – psychological placebo, PT – play thera-
py, PST – problem-solving therapy, DYN – psychodynamic therapy, SUP – supportive therapy, TAU – treatment-as-usual, WL – waitlist
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psychological placebo, treatment-as-usual, 
and no-treatment (SMDs ranged 
from 20.78 to 21.08), while CBT was not 
superior to any control condition.
There was no significant heterogeneity
in the network meta-analysis concerning
efficacy at post-treatment (SD50.38; 95%
CrI: 0.25 to 0.53), efficacy at follow-up
(SD50.12; 95% CrI: 0.01 to 0.31), and
acceptability (SD50.69; 95% CrI: 0.25 to
0.98), which suggests good interpretability
of the results. There was very little evidence
that direct and indirect effects were
inconsistent (95% CrIs of differences
between direct and indirect estimates
included 0).
Forest plots of the network meta-
analysis results for efficacy at post-
treatment and at follow-up, with 
psychological placebo as reference, are 
shown in Figure 5. We also created 
hierarchies of effect size on the basis of 
SUCRA rankings for efficacy outcomes. 
The best treatment, according to the 
curves, was IPT at post-treatment 
(SUCRA590.5%) and at follow-up 
(SUCRA590.3%). The worst treatment, 
according to the curves, was waitlist at 
post-treatment (SUCRA59.39%) and at 
follow-up (SUCRA56.26%).
There was no evidence that the treat-
ment effect was significantly modified by 
patients’ clinical characteristics or risk of 
bias in the trials. However, IPT and CBT 
had less significant effects in studies in 
which patients were children, comorbid 
psychiatric disorders were present, and the 
year of publication was 2000 or following.
DISCUSSION
Our review of 52 RCTs suggests that, 
among the psychotherapies tested in 
children and adolescents with depression, 
only IPT and CBT are significantly more 
benefi-cial than most control conditions at 
post-treatment and at follow-up. 
Compared with other psychotherapeutic 
interventions, IPT and CBT were 
significantly more effective than play 
therapy at post-treatment, and more 
effective than problem-solving therapy at 
follow-up. Psychodynamic therapy and 
play therapy were not significantly more 
effective than waitlist in reducing 
depression symptoms at post-treatment 
and follow-up, although
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the limited number of trials available suggests the need for
further research.
The acceptability of psychotherapies for depressed 
children and adolescents has seldom been investigated in 
previous meta-analyses. We found that IPT and problem-
solving therapy had significantly fewer all-cause 
discontinuations than CBT and cognitive therapy. A 
possible interpretation is that a protocol putting emphasis 
on cognitive changes is more difficult for young people to 
engage in.
Our finding that waitlist was inferior to other control 
conditions (including no-treatment, treatment-as-usual and 
psy-chological placebo) seems to support the idea that 
waitlist may act as a “nocebo condition” in psychotherapy 
trials (98). In the case of child and adolescent depression, 
alternative hypotheses may be proposed to interpret this 
finding. First, placebo response in child and adolescent 
depression may be particularly high (17,99). Second, patients 
who are allocated to no-treatment may actively seek other 
treatments, while those on waitlist do not, as they are waiting 
for the intervention to be delivered (98). Anyway, the use of 
waitlist may inflate the treatment effect of psychotherapies in 
clinical trials, and the use of psychological placebo or 
treatment-as-usual is likely to provide a more robust 
comparison.
In our analysis, IPT and CBT demonstrated a robust 
effect over short-term follow-up, but only IPT had a benefi-
cial effect over long-term follow-up. The theory behind IPT 
may particularly ring true for young people, as interpersonal 
difficulties may be more likely to drive psychopathology at 
this age (100). However, this finding was based on few trials, 
and requires further validation.
Subgroup analyses suggested no significant moderation 
of the treatment effect by different patient characteristics 
and intervention settings. Nonetheless, compared to psy-
chological placebo, IPT and CBT showed less robust effects 
in studies on children with depression or on patients with 
comorbid disorders, and in more recently published trials. 
These findings are consistent with those from previous liter-
ature (26,101,102), but require further confirmation due to 
the relatively small size of the subgroups.
There were some limitations in the current study. 
Network meta-analysis assumes that some treatment arms 
are similar in rationale and procedure, allowing us to group 
them together as one node in the network (103). However, 
the classification of psychotherapeutic interventions for 
child and adolescent depression remains provisional. For 
instance, the treatments implemented in the trials we 
included under the heading “family therapy” were some-
what heterogeneous. Moreover, treatment-as-usual may be 
very different in various mental health care contexts, and it 
may be difficult to differentiate between no-treatment and 
treatment-as-usual in clinical practice, because when some-
one is assigned to no treatment, he/she can seek some form 
of usual care (98).
We excluded studies on treatment-resistant depression
and psychotic depression, to reduce heterogeneity and
inconsistency among trials. This may have led, however, to
an overestimation of the effect size in the present meta-
analysis, because the most difficult cases were not 
considered. Also, we could not include data on adverse 
effects, cost-effectiveness, quality of life outcomes and 
suicide, because they were lacking in almost all studies, 
although these variables are important for clinicians and 
patients to make decisions on selecting appropriate 
treatment.
In conclusion, our review supports the notion that IPT 
and CBT, when available, should be the initial choice of 
psychological treatment for depression in children and 
adolescents. However, several alternative treatment 
options are understudied in this age group, and further 
research on moderators of treatment effect are needed. 
Waitlist may inflate the treatment effect of 
psychotherapies, and psycho-logical placebo or treatment-
as-usual are likely to provide a more robust comparison in 
psychotherapy trials.
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